Type of ALL-B-lymphoblastic leukemia/lymphoma - Page 2 of 2 Posts on Medivizor
Navigation Menu

Type of ALL-B-lymphoblastic leukemia/lymphoma Posts on Medivizor

Inotuzumab ozogamicin for patients with relapsed/unresponsive acute lymphoblastic leukemia

Posted by on Apr 24, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term safety and effectiveness of inotuzumab ozogamicin (Besponsa) for patients with relapsed or unresponsive acute lymphoblastic leukemia.   This study concluded that this treatment was safe and effective for these patients. Some background Inotuzumab ozogamicin (InO) is a targeted...

Read More

Looking for young patients with B-cell acute lymphoblastic leukemia to test a new T-cell therapy

Posted by on Apr 22, 2019 in Leukemia | 0 comments

In a nutshell This phase 2 trial is evaluating the effectiveness of huCART19 cell therapy in young patients with high-risk B-cell acute lymphoblastic leukemia (ALL). The main outcome to be measured will be survival without a treatment-related complication. This study is being conducted in Philadelphia, Pennsylvania, United States. The details Acute...

Read More

CAR-T cell therapy and infection risk

Posted by on Dec 16, 2017 in Leukemia | 0 comments

In a nutshell This study examined infection risk in leukemia and lymphoma patients treated with CAR-T cell therapy, a new type of immunotherapy. Researchers reported that infection rates were comparable to other salvage therapies.  Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In...

Read More

CAR-T cell therapy and infection risk

Posted by on Dec 16, 2017 in Leukemia | 0 comments

In a nutshell This study examined infection risk in leukemia and lymphoma patients treated with CAR-T cell therapy, a new type of immunotherapy. Researchers reported that infection rates were comparable to other salvage therapies.  Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In...

Read More

Blinatumomab: A new monoclonal antibody therapy as a treatment option for relapsed B-cell ALL

Posted by on Mar 21, 2017 in Leukemia | 0 comments

In a nutshell This study examined remission rates with blinatumomab (Blincyto) treatment in patients with relapsed adult acute lymphoblastic leukemia (ALL). Researchers concluded that blinatumomab can achieve complete remission in patients with unfavorable ALL. However, this was an early-phase trial and more studies are needed. Some background...

Read More